When you purchase through links on our site , we may earn an affiliate delegation . Here ’s how it works .
adopt drugs like Ozempic for weight loss may issue forth with a slight risk of exposure of severe gastrointestinal ( GI ) problem , including inflammation of the pancreas and too - dense stomach movements , sometimes called " stomach paralysis . "
That ’s agree to a new study published Thursday ( Oct. 5 ) in the journalJAMA . In the work , scientist liken the rate of serious gilbert trouble in mass who take on Ozempic - same drug , call GLP-1 protagonist , for weight red with the charge per unit see in multitude who guide a different character of weight - loss drug squall bupropion - naltrexone .
Drugs like Ozempic are called GLP-1 agonists, and they may come with a small risk of GI conditions.
Those who took GLP-1 agonists had higher rates of bowel obstacle , pancreatitisand gastroparesis . Also called " stomach palsy " or " delayed gastric emptying , " gastroparesis refers tothe slowing or stopping of stomach contractions , which causes food to linger too long and potentially mould masses called " bezoars . "
" yield the wide manipulation of these drugs , these adverse event , although rare , must be believe by affected role thinking about using them for weight red ink , " sketch first authorMohit Sodhi , a medical scholar at the University of British Columbia , said in astatement .
Related : Can Ozempic and Wegovy cause ' venter paralysis ' and ' cyclic vomiting ' ?
That ’s especially true for people who do not have diabetes , because the drug were originally approved to treattype 2 diabetes . Thus , the most full-bodied research into their side effects come from multitude with the condition . However , the drugs have also been prescribed " off - recording label " for weight red , and since 2021 , there are versions of the drugs specifically marketed for weight red . ( Ozempic , for object lesson , is approved for diabetes , but the same drug is now uncommitted under the name Wegovy as a system of weights - exit discussion . )
Recent trials that analyse GLP-1 agonists for weight loss were limited in their size and length , which left a gap in our understanding of the drugs ' side force , the author write in their paper . People with diabetes have an exalted risk of severe GI issues at baseline , so the risks for people without diabetes may take issue , they noted .
" People who are otherwise levelheaded may be less willing to accept these potentially serious adverse events , " Sodhi said .
— Could Ozempic be used to cover habituation ? Studies suggest yes , but question stay
— Watch out for Ozempic emulator containing unauthorized fighting ingredients , FDA warns
— Common exercising weight - loss surgery for teenager may counteract their bones
The fresh subject used PharMetrics Plus , a massive database of wellness insurance claims filed in the U.S. In the datum , the squad identified the great unwashed who took the GLP-1 agonists semaglutide and liraglutide ; semaglutide is in Ozempic and Wegovy , while liraglutide is in Saxenda . All of these drug play bymimicking a internal secretion that help master appetiteand the upper at which the stomach empties .
The squad compare GLP-1 user with those taking bupropion - naltrexone , a different weightiness - loss drug thatworks by tweaking signals in the psyche ’s reward centerthat would usually spur a person ’s appetite . About 650 the great unwashed in the study were taking bupropion - naltrexone , 600 were taking semaglutide and 4,100 were take aim liraglutide . All of the participants had obesity but not diabetes .
equate with bupropion - naltrexone users , GLP-1 users had a approximately nine-fold great risk of infection of pancreatitis , a fourfold higher risk of intestine obstruction , and a 3.6 times eminent endangerment of gastroparesis .
The overall pace of these precondition was still fairly low , though . For lesson , out of 1,000 people taking semaglutide for one twelvemonth , there were about five cases of pancreatitis . Among liraglutide users , there were closer to eight case . Gastroparesis affect about 10 in 1,000 semaglutide exploiter and 7 in 1,000 liraglutide users in a year . Bowel obstruction affect 8 in 1,000 liraglutide users , but there were no cases among semaglutide exploiter .
doc told NBCthat they inquire whether some of these side effects were linked to the patients ' rapid weight going , rather than to the specific drugs used . Others said the cogitation was unlikely to deepen how they prescribe GLP-1 agonist , but it does emphasize that patients should be close monitored by their health guardianship provider while contract the drug .
This article is for informational aim only and is not meant to offer medical advice .
